Respiratory Muscles After Inspiratory Muscle Training After COVID-19
NCT ID: NCT05582642
Last Updated: 2026-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2022-10-17
2024-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Respiratory Muscle Assesment in COVID-patients Without Hospitalization
NCT06105450
Respiratory Muscles After Hospitalisation for COVID-19
NCT04854863
Inspiratory Muscle Training and Hospital Complications
NCT02459444
Inspiratory Muscle Training in Post COVID-19 Infection Subjects
NCT05282199
Effects of Respiratory Muscle Training in Individuals With Long-term Post-COVID-19 Symptoms
NCT05597774
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The respiratory muscles are the muscle groups that cause the expansion and contraction of the chest during inhalation and exhalation. The most important respiratory muscle is the diaphragm. It is known that long-term ventilation in the intensive care unit weakens the respiratory muscles, since the work of the muscles is taken over by the ventilation devices and the muscles are not trained over a long period of time.
As recently shown, COVID-19 disease can lead to diaphragmatic weakness even in the absence of ventilation.
In this project (CTCA 20-515) the present investigators demonstrated that several patients after COVID-19 suffer from diaphragmatic weakness. Specifically, diaphragmatic weakness also related to shortness of breath complained about by patients and currently not otherwise explainable.
The so-called inspiratory muscle training (IMT or diaphragm training) is known in pneumological rehabilitation for years. In the current project, after the training has been explained, the patient is asked to breathe against resistance at home using a small mouthpiece and a small device several times (twice) a day and several times a week (each day).
This procedure is considered safe and very effective in training the diaphragm. Accordingly, it is the aim of the current (follow-up) project for the first time in post-COVID patients who continue to complain of shortness of breath and for whom there is no other explanation than possibly the proven diaphragmatic weakness, to determine the effects of 6 weeks of IMT/diaphragm training on diaphragm strength and on shortness of breath.
At the beginning and at the end of the 6 weeks of training, the present investigators would carry out the all-encompassing measurement of diaphragm force, which is known to patients and explained again below. Furthermore, the present investigators would invite patients twice a week to optimize the training together (for a maximum of 1 hour per appointment). This would take place once a week in the present investigators laboratory for respiratory physiology and the training would be improved it if necessary, once a week.
The training would end after 6 weeks and the present investigators would measure diaphragm function again 6 weeks after the training, i.e. a third time in total, to determine whether the effects seen continue to be present after the training. After that, the study ends.
The present investigators would offer the treatment arm (the 9/18 patients) in whom diaphragm endurance training was carried out as a control of the diaphragmatic strength training to carry out strength training after the measurement 6 weeks after the end of the therapy (outside of this study here as a purely clinical therapy).
The training itself includes 2 x 30 breathing cycles per day. Patients can divide these 2 x 30 breathing cycles freely, i.e. specifically train 1 x 30 breathing cycles in the morning and 1 x 30 breathing cycles in the afternoon. The whole training should take place daily, 7 days a week.
Once a week the present investigators get a picture of the patient's training, pay attention to shortness of breath, potential for adaptation (also specifically for even stronger training, if tolerated by the patients, increase in training, i.e. the breathing resistance that patients would have to overcome when inhaling ).
In the "control" arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diaphragm Strength Training
Inspiratory Muscle Training (IMT)
The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.
In the "control" arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above).
Diaphragm Endurance Training
Inspiratory Muscle Training (IMT)
The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.
In the "control" arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inspiratory Muscle Training (IMT)
The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.
In the "control" arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged at least 18 years, who are mentally and physically able to consent and participate into the study
Exclusion Criteria
* Body-mass-index (BMI) \>40
* Expected absence of active participation of the patient in study-related measurements
* Alcohol or drug abuse
* Metal implant in the body that is not MRI compatible (NON MRI compatible pacemaker, implantable defibrillator, cervical implants, e.g. brain pacemakers etc.)
* Slipped disc
* Epilepsy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philipps University Marburg
OTHER
RWTH Aachen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jens Spießhöfer
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens Spiesshoefer, MD
Role: PRINCIPAL_INVESTIGATOR
RWTH Aachen University
Binaya Regmi, MD
Role: STUDY_CHAIR
RWTH Aachen University
Michael Dreher, Professor
Role: STUDY_DIRECTOR
RWTH Aachen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RWTH Aachen University
Aachen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Daher A, Balfanz P, Aetou M, Hartmann B, Muller-Wieland D, Muller T, Marx N, Dreher M, Cornelissen CG. Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. Sci Rep. 2021 Jan 26;11(1):2256. doi: 10.1038/s41598-021-81444-9.
Daher A, Balfanz P, Cornelissen C, Muller A, Bergs I, Marx N, Muller-Wieland D, Hartmann B, Dreher M, Muller T. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respir Med. 2020 Nov-Dec;174:106197. doi: 10.1016/j.rmed.2020.106197. Epub 2020 Oct 20.
Balfanz P, Hartmann B, Muller-Wieland D, Kleines M, Hackl D, Kossack N, Kersten A, Cornelissen C, Muller T, Daher A, Stohr R, Bickenbach J, Marx G, Marx N, Dreher M. Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19. PLoS One. 2021 Jan 29;16(1):e0246182. doi: 10.1371/journal.pone.0246182. eCollection 2021.
Spiesshoefer J, Friedrich J, Regmi B, Geppert J, Jorn B, Kersten A, Giannoni A, Boentert M, Marx G, Marx N, Daher A, Dreher M. Diaphragm dysfunction as a potential determinant of dyspnea on exertion in patients 1 year after COVID-19-related ARDS. Respir Res. 2022 Jul 15;23(1):187. doi: 10.1186/s12931-022-02100-y.
Spiesshoefer J, Henke C, Herkenrath S, Brix T, Randerath W, Young P, Boentert M. Transdiapragmatic pressure and contractile properties of the diaphragm following magnetic stimulation. Respir Physiol Neurobiol. 2019 Aug;266:47-53. doi: 10.1016/j.resp.2019.04.011. Epub 2019 Apr 25.
Spiesshoefer J, Henke C, Herkenrath S, Randerath W, Brix T, Young P, Boentert M. Assessment of Central Drive to the Diaphragm by Twitch Interpolation: Normal Values, Theoretical Considerations, and Future Directions. Respiration. 2019;98(4):283-293. doi: 10.1159/000500726. Epub 2019 Jul 26.
Spiesshoefer J, Herkenrath S, Henke C, Langenbruch L, Schneppe M, Randerath W, Young P, Brix T, Boentert M. Evaluation of Respiratory Muscle Strength and Diaphragm Ultrasound: Normative Values, Theoretical Considerations, and Practical Recommendations. Respiration. 2020;99(5):369-381. doi: 10.1159/000506016. Epub 2020 May 12.
Spiesshoefer J, Regmi B, Senol M, Jorn B, Gorol O, Elfeturi M, Walterspacher S, Giannoni A, Kahles F, Gloeckl R, Dreher M. Potential Diaphragm Muscle Weakness-related Dyspnea Persists 2 Years after COVID-19 and Could Be Improved by Inspiratory Muscle Training: Results of an Observational and an Interventional Clinical Trial. Am J Respir Crit Care Med. 2024 Sep 1;210(5):618-628. doi: 10.1164/rccm.202309-1572OC.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTCA 250-22 / 22-241
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.